These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 30732592)
21. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759 [TBL] [Abstract][Full Text] [Related]
22. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555 [TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians. Schousboe JT; Landsteiner A; Drake T; Sultan S; Langsetmo L; Kaka A; Anthony M; Billington CJ; Kalinowski C; Ullman K; Wilt TJ Ann Intern Med; 2024 May; 177(5):633-642. PubMed ID: 38639547 [TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Deacon CF Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230 [TBL] [Abstract][Full Text] [Related]
25. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Cornell S J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069 [TBL] [Abstract][Full Text] [Related]
26. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. Luconi M; Cantini G; Ceriello A; Mannucci E Int J Cardiol; 2017 Aug; 241():302-310. PubMed ID: 28285800 [TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055 [TBL] [Abstract][Full Text] [Related]
28. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Kohro T; Yamazaki T; Sato H; Harada K; Ohe K; Komuro I; Nagai R Int Heart J; 2013; 54(2):93-7. PubMed ID: 23676369 [TBL] [Abstract][Full Text] [Related]
29. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Liu X; Men P; Wang Y; Zhai S; Liu G Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. Ha KH; Kim B; Choi H; Kim DJ; Kim HC Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719 [TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients. Li SY; Chen HH; Lai CC; Lin CL; Kao CH QJM; 2020 Mar; 113(3):181-185. PubMed ID: 31584671 [TBL] [Abstract][Full Text] [Related]
34. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study. Narasaki Y; Kovesdy CP; You AS; Sumida K; Mallisetty Y; Surbhi S; Thomas F; Amin AN; Streja E; Kalantar-Zadeh K; Rhee CM Lancet Reg Health Am; 2024 Aug; 36():100814. PubMed ID: 38993538 [TBL] [Abstract][Full Text] [Related]
35. Update on incretin hormones. Phillips LK; Prins JB Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749 [TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741 [TBL] [Abstract][Full Text] [Related]
37. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Cho YY; Cho SI Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797 [TBL] [Abstract][Full Text] [Related]
38. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Kridin K; Amber K; Khamaisi M; Comaneshter D; Batat E; Cohen AD Immunol Res; 2018 Jun; 66(3):425-430. PubMed ID: 29855994 [TBL] [Abstract][Full Text] [Related]
39. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE; Lau J; Pittas AG JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]